News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmusanT, Inc. Relocates Offices to State-of-the-Art Innovation Facility


8/16/2012 10:42:44 AM

CAMBRIDGE, Mass., Aug. 16, 2012 /PRNewswire/ -- ImmusanT, Inc. announced today that it has relocated its operations to One Kendall Square, a 676,000-square-foot, mixed-use campus in the heart of Cambridge. The facility allows ImmusanT to establish a state-of-the-art lab for conducting immunologic assays to support its development efforts and clinical trials in celiac disease and other autoimmune diseases.

One Kendall Square is a nine-building campus located just minutes from Massachusetts Institute of Technology offering office, laboratory and retail space. Building 200 offers new incubator space and provides ImmusanT with its own lab facility as well as shared services that allow the company to remain capital efficient as it advances its development and discovery programs. The ImmusanT lab will specialize in a variety of high-throughput immune monitoring techniques, and the accompanying office space will accommodate the company's small executive team.

"We spent a considerable amount of time assessing options to allocate our resources toward our offices and lab. At One Kendall Square we're part of a thriving hub of innovation and it's a great environment in which to build our business," said Leslie Williams, President and CEO of ImmusanT. "Our new immune monitoring lab will allow us to sustain and better monitor critical aspects of our Nexvax2® development program and we feel it is vital in ensuring efficiency, quality and retention of expertise in-house."

ImmusanT worked directly with its broker, T3 Advisors to complete the lease agreement with The Beal Companies.

About ImmusanT, Inc.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information can be found at www.ImmusanT.com.

SOURCE ImmusanT, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES